NCT06487702View on ClinicalTrials.gov

A Phase lb/lI Clinical Study in Advanced or Metastatic Esophageal Squamous Cell Carcinoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

July 10, 2024

Primary Completion Date

June 10, 2026

Study Completion Date

June 10, 2027

Conditions
Esophageal Squamous Cell Carcinoma
Interventions
DRUG

fruquintinib++Candonilimab+ Tegafur，Gimeracil and Oteracil Potassium

"Fruquintinib administration for 2 weeks followed by 1-week break~Candonilimab：10 mg/kg，D1，Q3W；~Tegafur，Gimeracil and Oteracil Potassium：30mg BID for body surface area \< 1.25 m2; 40mg BID for body surface area of 1.25-1.5 m2; and 50mg BID for body surface area \>1.5 m2; D1-14, q3w"

Trial Locations (1)

510060

Medical Oncology,Sun Yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Rui-hua Xu, MD, PhD

OTHER